Summary
Objective
To estimate costs and benefits of a preventive anti-influenza vaccination in a group of employees of Snamprogetti (an ENI-group company), in order to define a scheme of cost-benefit analysis to be used for other strategies of vaccination and in other contexts.
Design
In an observational study conducted from October 1999 to June 2000, 153 employees (about 10% of the whole staff of Snamprogetti), who voluntarily underwent the vaccination, were compared with 153 non-vaccinated people working in the same context and matched for age and gender. The outcome was evaluated by checking records from the personnel department about absence from work and related causes, including influenza. Costs and benefits of the anti-influenza vaccination from the Snamprogetti point of view were subsequently calculated.
Results
The anti-influenza vaccination strategy reduced the absence of people from work by 77% and decreased the loss of working days by 82%. The ratio between the benefits of the vaccination strategy (less working days lost) and its costs was 12.12. The ratio remains favourable when the mean cost of a working day for the enrolled employees is used, resulting in a benefit-cost ratio of 9.45.
Conclusions
The results of this study suggest that the implementation of the anti-influenza vaccination strategy in Snamprogetti was cost saving. The cost-benefit analysis used in this study could also be used for other vaccination strategies and in other contexts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Bibliografia
Cate TR. Clinical manifestations and consequences of influenza. Am J Med 1987; 82: 15–9
Neuzil KM, Reed GW. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281(10): 901–7
Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics 1996; 9 (suppl. 3): 75–8
Ministero della Sanità. Circolare n. 11/1999. Profilassi antinfluenzale.
Sullivan KM. Health impact of influenza in the United States. PharmacoEconomics 1996; 9 (suppl. 3): 26–33
Knottnerus JA. Influenza in the Netherlands. PharmacoEconomics 1996; 9 (suppl. 3): 46–9
Gasparini R, Pozzi T, Bonanni P, Fragapane E. Valutazione dei costi di un’epidemia influenzale nella popolazione lavorativa di Siena. Giornale di Farmacoeconomia 2000; 1: 3–9
Postma MJ, Bos JM, Van Gennep M. Economic evaluation of influenza vaccination. PharmacoEconomics 1999; 16 (suppl. 1): 33–40
Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 1997; 29: 181–5
Levy E. French economic evaluations of influenza and influenza vaccination. PharmacoEconomics 1996; 9 (suppl. 3): 62–6
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333(14): 889–93
Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281(10): 908–13
Breiman RF, Butler JC, McInnes PM. Vaccine to prevent respiratory infection: opportunities on the near and far horizon. Current Opinion in Infectious Diseases 1999; 12: 145–52
Drummond MF, Stoddard GL, Torrance GW. Methods for the economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications, 1997
Sloan FA. Valuing Health Care. Cambridge: Cambridge University Press, 1995
Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics 1992; 1(1): 20–32
Lucioni C. Costi e benefici della vaccinazione. Vaccinazione 2000 1995; 7, 37 (suppl.): 31–7
Sobal J, Loveland FC. Infectious disease in a total institution: a study of the influenza epidemic of 1978 on a college campus. Public Health Rep 1982; 97(1): 66–72
Lucioni C, Sessa A, Costa B. I costi dell’influenza in Italia. Farmeconomia e percorsi terapeutici 2001; 1(1): 11–8
Koplan JP. The benefits and costs of immunization revisited. Drug Information Journal 1988; 22: 379–83
van der Oever R, de Graeve D, Hepp B, et al. Pharmaeconomics of immunization. A review. PharmacoEconomics 1993; 3(4): 286–308
Conway SP, Leese B. Routine childhood immunisation. It is worth it? PharmacoEconomics 1993; 3(3): 183–91
ISTAT. Rivalutazione monetaria. Indici prezzi al consumo 2001. Consultabile all’indirizzo http://www.istat.it/Anotizie/Acom/pre-con/indiceistat/variazioni.htm
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Colombo, G.L., Nicosia, V., Lesma, A. et al. Analisi costi-benefici di una strategia vaccinale antinfluenzale condotta presso una società del gruppo ENI (Snamprogetti). Pharmacoeconomics-Ital-Res-Articles 3, 71–80 (2001). https://doi.org/10.1007/BF03320581
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320581